A Phase 1, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3403 in Healthy Volunteers and Subjects With Elevated LDL-C
Latest Information Update: 07 Feb 2024
At a glance
- Drugs SGB 3403 (Primary) ; Atorvastatin
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors SanegeneBio
Most Recent Events
- 11 Oct 2023 New trial record
- 07 Oct 2023 According to a SanegeneBio media release, company has obtained an implicit approval of clinical trial application for the treatment of hypercholesterolemia in China (acceptance number CXHL2300741).